Official journal of JSPHCS
Multidisciplinary intervention for adverse events associated with ATZ + BEV therapy: a case report
Atezolizumab (ATZ) plus bevacizumab (BEV) combination therapy has recently been approved for the treatment of unresectable hepatocellular carcinoma. However, immune-related adverse events (irAEs), including pe...